Q-omics provides the consensus-scored SYNGR2 profile across patient tissues and cancer cell-line models. SYNGR2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SYNGR2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SYNGR2 protein abundance shows 21,150 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, KIRC, and GBM as cancer lineages where SYNGR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNGR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNGR2 survival associations across molecular data types. SYNGR2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNGR2 RNA expression–survival associations across cancer types. High SYNGR2 expression shows unfavorable associations in LIHC, LGG, KIRP and GBM, but favorable associations in SARC and CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SYNGR2 RNA expression.
This table summarizes SYNGR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SYNGR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNGR2 shows lower tumor expression in KICH and higher tumor expression in KIRC, BLCA, COAD, KIRP and HNSC. The KIRC box plot shows higher SYNGR2 RNA expression in tumor versus normal tissue (log2 FC = +0.775, t-test p < 0.001).
This table shows molecular features associated with SYNGR2 in patient tissues and cancer cell lines. In patient samples, SYNGR2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNGR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BREAST.
